Ola Landgren, MD, PhD

home / authors / ola-landgren-md-phd

Ola Landgren, MD, PhD, is the chief of the myeloma division and leader of the experimental therapeutics program at Sylvester Comprehensive Cancer Center at the University of Miami Health System. He is also a professor of medicine at the University of Miami.

Articles

June 12th 2025

ADVANCE Trial Supports DKRd as New Standard of Care for Newly Diagnosed Multiple Myeloma: Ola Landgren, MD, PhD

Brooke McCormick Ola Landgren, MD, PhD

Ola Landgren, MD, PhD, shares ADVANCE trial results, which show that adding daratumumab to carfilzomib-lenalidomide-dexamethasone (DKRd) improves outcomes in newly diagnosed multiple myeloma.

June 12th 2025

ADVANCE Trial Aims to Modernize Frontline Multiple Myeloma Care: Ola Landgren, MD, PhD

Brooke McCormick Ola Landgren, MD, PhD

Ola Landgren, MD, PhD, lead investigator of the ADVANCE clinical trial, outlines the study’s goal of advancing modern, minimal residual disease–guided treatment approaches.

June 6th 2025

Advancing Care, Addressing Ongoing Challenges at the EHA 2025 Congress: Ola Landgren, MD, PhD

Brooke McCormick Ola Landgren, MD, PhD

Ahead of the 30th European Hematology Association (EHA) Congress in Milan, Ola Landgren, MD, PhD, shares what he is most looking forward to and reflects on key advancements and ongoing challenges in hematology.